secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2024-02-02T23:59:59+00:00
Accession:  0001551152-24-000007
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie Q4 adj. EPS $2.79, revenue $14.3B; FY2024 adj. EPS guidance $11.05-$11.25
--------------------------------------------------------------------------------

- Full-year 2023 GAAP EPS $2.72 (-59%); adjusted EPS $11.11 (-19.3%); revenue $54.3B (-6.4%).
- Q4 2023 GAAP EPS $0.46 (-66.7%); adjusted EPS $2.79 (-22.5%); revenue $14.3B (-5.4%).
- Humira Q4 revenue $3.3B (-40.8% on biosimilar competition); Skyrizi up 51.9%; Rinvoq up 62.9%.
- Announced ImmunoGen acquisition (~$10.1B equity) and Cerevel (~$8.7B); expected close mid-2024.
- FY2024 adj. EPS guidance $11.05-$11.25 includes $0.32 dilution from pending deals; long-term CAGR reaffirmed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115224000007/0001551152-24-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115224000007/abbv-20240202.htm
  HTML page:      https://secwatch.observer/filing/0001551152-24-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer